Current Status of Newborn Screening in Europe

J. Gerard Loeber

Based on an ISNS survey held during 2018

(publication in preparation)
Acknowledgement

All ISNS members and other colleagues who replied to the survey.
No data for Albania, Azerbaijan, Kosova, some for Moldova, Turkey, Ukraine
Age at blood sampling (2018)

- < 48 h
- > 48 h
- > 72 h
- 4-7 days
Notes

- Finland has introduced heel prick screening since 2015, in transition period cord blood for CH-screening
- Malta is piloting with heel prick screening, probably 2017
Interval sampling- analysis (2018)
Notes

- Large variations in times needed for sending the cards
- When screening result is too late the infant may have died or suffered clinically, screening is then of less value.
Phenylketonuria (2018)

Not in Azerbaijan, Malta, Montenegro
Not in Moldova, pilot in Azerbaijan
Congenital Adrenal Hyperplasia (2018)

Pilot in Belgium-Wallonia, Italy
Cystic Fibrosis (2018)

Pilot in Hungary, North Macedonia
Biotinidase deficiency (2018)
Number of disorders detected by MS / MS (2018)

- > 6
- 1-6
- pilot/partly
Pilot in Finland, Italy, Netherlands, Spain, Sweden
Number of conditions per country (2018)
Conclusions about NBS in Europe (2018)

- No NBS: Albania
- Number of conditions varies largely per country (1 - 30)
- Number of conditions screened is not related to GNP
- Unclear if W&J criteria are used in decisions on NBS expansions